• Macquarie University research project on formulation of inhaled dry powder biologics will involve Aptar Pharma’s Orbital DPI

  Aptar Pharma has announced that its Orbital high-payload dry powder inhaler will be key to a Macquarie University research project titled “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” which is funded by a… [Read more . . .]

• AstraZeneca’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI approved by the EU for the treatment of asthma

  AstraZeneca announced that the European Commission has approved the company’s Trixeo (Breztri) Aerosphere budesonide / glycopyrrolate / formoterol MDI for the treatment of asthma in patients aged 12 and older whose asthma is not adequately… [Read more . . .]

• CF Pharmtech initiates Phase 1 trial of ICF004 antifibrotic DPI

  Chinese OINDP developer CF Pharmtech has announced the initiation of its Phase 1 trial of its ICF004 dry powder inhaler, which the company is developing for the treatment of fibrotic lung diseases. The study record… [Read more . . .]

• Polyrizon initiates trial of Nasarix (PL-14) intranasal allergen blocker for seasonal allergic rhinitis

  Polyrizon has announced the initiation of its first clinical trial, a study of its Nasarix (PL-14) hydrogel nasal spray in patients with seasonal allergic rhinitis. In September 2025, the company said that it had submitted… [Read more . . .]

• Bespak and Upperton team up to offer nasal drug development and manufacturing services

  OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer services based on Upperton’s UpperNose nasal development platform and manufacturing capability in conjunction with Bespak nasal delivery devices. The announcement… [Read more . . .]

• FDA accepts Insmed’s sNDA to expand the use of Arikayce amikacin liposome inhalation suspension for MAC lung disease

• SpliSense initiates Phase 2b trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic fibrosis

• FDA clears IND for Phase 1b trial of SMSbiotech’s inhaled stem cell therapy in patients with COPD

• Ritedose Corporation names Carolyn Berg as VP of Strategic Growth

• FDA approves Aurobindo’s generic beclomethasone MDI

More news . . .